Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 (sacituzumab tirumotecan) plus apatinib for third-line advanced gastric cancer
ChiCTR2500109428Phase 2Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and Rivoceranib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Objective Response Rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanRivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500109428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109428.